Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002307
Status:
COMPLETED
Last Update Posted:
2011-08-05
First Post:
1999-11-02
Brief Title:
A Comparison of Zidovudine AZT and Stavudine in HIV-Infected Patients
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Double-Blind Comparison of Zidovudine AZT Versus Stavudine d4T BMY 27857 for the Treatment of Patients With HIV Infection Who Have Absolute CD4 Lymphocyte Counts Between 50 and 500 Cellsmm3
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare stavudine d4T and zidovudine AZT in slowing the progression of HIV disease To compare the antiviral activity of d4T versus AZT as measured by plasma levels of p24 antigen and HIV viremia and their relative efficacy by improvement andor absence of adverse changes over time in laboratory parameters associated with HIV infection To compare the safety of oral doses of d4T to AZT in patients with HIV infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI455-019 | None | None | None |